Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) a leader in the development of diagnostic and prognostic tests ...

A research team led by Erwin F. Wagner from the Medical University of Vienna has discovered a previously unknown molecular ...

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies ...

Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens ...

A research team led by Erwin F. Wagner from the Medical University of Vienna has discovered a previously unknown molecular ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

Hearing scheduled for Scripps Park sidewalk widening A city of San Diego hearing officer is scheduled to consider plans to ...

Cancer isn't just about broken genes-it's about broken architecture. Imagine a city where roads suddenly vanish, cutting off neighborhoods from essential services.

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, ...

A single signaling pathway controls whether immune cells attack or befriend cells they encounter while patrolling our bodies, researchers at Stanford ...

The immunotherapies used to treat melanoma now include well-established drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) and newer ones such as Amtagvi (lifileucel), which uses T cells ...

BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...